Perspective
The Emergency Use Authorization of Peramivir for Treatment of 2009 H1N1 Influenza
N Engl J Med 2009; 361:2204-2207December 3, 2009
- Article
On October 23, 2009, Food and Drug Administration (FDA) Commissioner Margaret Hamburg issued an Emergency Use Authorization (EUA) for peramivir for intravenous injection (BioCryst Pharmaceuticals). Peramivir is an unapproved investigational neuraminidase inhibitor that may be effective in treating certain hospitalized adult and pediatric patients with suspected or confirmed cases of 2009 H1N1 influenza. The EUA allows health care providers to use peramivir, subject to specified conditions. This is the first EUA that has been issued for an unapproved drug.
The legal standard for the authorization of an EUA during a declared public health emergency requires a finding that it is “reasonable to believe” that the product “may be effective,” as well as a finding that its known and potential benefits outweigh its known and potential risks.1 There must also be no other adequate, approved, and available treatment alternatives for the specific indication. This is a lower evidentiary standard than that used for marketing approval, which requires a finding of “substantial evidence” of efficacy for the proposed use based on adequate and well-controlled trials, as well as a robust safety evaluation (see table
Criteria for Emergency Use Authorizations (EUAs), Investigational New Drug Applications (INDs), Emergency Investigational New Drug Applications (EINDS), and FDA-Approved Prescription Products.).The FDA's authority to issue an EUA was granted by Congress in the Project Bioshield Act of 2004. An EUA can be issued only after the secretary of health and human services has declared a public health emergency. In the case of the 2009 H1N1 influenza pandemic, such a declaration was made on April 26, 2009. An EUA for a medical product has a term of 1 year, but it can be renewed, depending on the circumstances of the emergency. It is important that product development continue to focus on the goal of approval (there are ongoing clinical trials evaluating the efficacy of intravenous peramivir in treating influenza), because the EUA is only a temporary means for making a product available during an emergency.
The FDA conducted an expedited review of the available data on peramivir, including data in preliminary or summary reports of clinical trials completed to date. Four efficacy trials evaluating the intravenous administration of peramivir have been completed; the details of these trials and information about the use of peramivir are summarized in the “Peramivir Fact Sheet for Health Care Providers” that was issued with the EUA.2 A treatment benefit — alleviation of symptoms approximately 1 day sooner than with placebo — was observed after the administration of single intravenous doses of 300 mg or 600 mg of peramivir in patients with acute, uncomplicated seasonal influenza. This treatment effect is similar to that seen with currently approved oral neuraminidase inhibitors. Two other trials of peramivir were conducted using oral oseltamivir as an active control (with no placebo group). No conclusions about efficacy can be drawn from the results of these trials because they did not demonstrate that peramivir was superior to oseltamivir and a clinically meaningful noninferiority margin for such a comparison has not been established. A fourth small trial revealed no significant differences in efficacy between two different doses of peramivir or between single and multiple doses. There are very limited data available regarding the use of peramivir in seriously ill hospitalized patients. Because the 2009 H1N1 virus is a novel influenza virus, trials of peramivir have not been conducted in patients with this infection. Overall, our determination that intravenous peramivir may be effective in treating hospitalized patients with 2009 H1N1 influenza was based on the drug's demonstrated activity as a neuraminidase inhibitor and the treatment benefit observed in patients with acute, uncomplicated influenza.
Under the EUA, the usual adult dose for peramivir is 600 mg administered intravenously once daily for 5 to 10 days. This dose was selected on the basis of findings of a treatment benefit at doses of 300 mg or 600 mg in acute, uncomplicated influenza; the expected proportionally greater exposure at 600 mg than at lower doses; and the consideration that patients with more severe disease may need a higher dose. The treatment duration was selected on the basis of the expected need for a longer duration in hospitalized patients and is consistent with the design of ongoing phase 3 trials in hospitalized patients. The available safety data, including data from the limited number of patients who received 600 mg daily for 5 or more days, supported the selection of this dose and duration under the EUA.
Only 1891 clinical trial subjects have received peramivir at any dose, in any formulation (intravenous or intramuscular), or for any duration, including 478 who received a single dose of 600 mg intravenously and 33 who received 600 mg (or more) intravenously once daily for 5 or more days. No pediatric patients have received peramivir in clinical trials. The most commonly reported adverse effects in clinical trials were diarrhea, nausea, vomiting, and neutropenia. A limited number of pediatric and adult patients have also received peramivir under Emergency Investigational New Drug (EIND) procedures.
The FDA determined that despite the limited data on efficacy and safety, the criteria for an EUA for peramivir had been met for the treatment of certain patients hospitalized with known or suspected 2009 H1N1 influenza. Specifically, it is reasonable to believe that peramivir may be effective in patients with the pandemic virus on the basis of the limited results available from trials in patients with seasonal influenza. Furthermore, the serious, and potentially fatal, nature of the disease observed to date in patients who have been hospitalized because of 2009 H1N1 influenza infection and the lack of alternative treatment options (i.e., an intravenous antiviral agent with activity against influenza) for many of these patients led to issuance of the EUA for peramivir.
The Centers for Disease Control and Prevention (CDC) is responsible for managing the drug's distribution and has established an electronic system through which health care providers can request peramivir under the EUA (www.cdc.gov/h1n1flu/eua/peramivir.htm). Currently, approximately 1200 treatment courses (if all given once daily for 5 days, or 600 treatment courses, if all given once daily for 10 days) of intravenous peramivir are available for distribution; more are expected to become available over time. The CDC will distribute peramivir directly to a hospital after verification of the request from a licensed clinician.
Health care providers and patients considering using peramivir under the EUA must carefully read the “Peramivir Fact Sheet for Health Care Providers” and the “Peramivir Fact Sheet for Patients and Parents/Caregivers” to assess the limited and preliminary nature of the available safety and efficacy data.2,3 Alternatives should be considered in making treatment decisions for individual patients who are hospitalized with 2009 H1N1 influenza.
Prescribing under the EUA is different from prescribing FDA-approved drugs (see table). Health care providers need to recognize that peramivir is an unapproved drug authorized for use only because of and during the 2009 H1N1 public health emergency. Although review by an institutional review board is not required, health care providers who prescribe the drug must fulfill certain requirements. These requirements are detailed in the “Peramivir Fact Sheet for Health Care Providers”2 and include documentation in the medical record that the patient and caregivers have been given the “Peramivir Fact Sheet for Patients and Parents/Caregivers,” informed of alternatives to receiving peramivir, and told that peramivir is an unapproved drug to be used only under the EUA. Providers must also report all medication errors and selected adverse events to the FDA's MedWatch program (www.fda.gov/medwatch/report.htm), after which the FDA may contact the provider for additional information.
Because of the severity of illness in some patients hospitalized with 2009 H1N1 influenza, it is expected that some patients may not survive, whether or not they are treated with peramivir. Furthermore, it is expected that the evaluation of adverse events will be complicated by patients' underlying medical conditions, coexisting conditions, and use of concomitant medications. Interpretation of the safety data will be challenging and complex. The FDA will carefully assess all available data on an ongoing basis and will update clinicians and the public as we learn more about this drug's safety.
Financial and other disclosures provided by the authors are available at NEJM.org.
This article (10.1056/NEJMp0910479) was published on November 2, 2009, at NEJM.org.
Source Information
From the Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
- References
References
1
Emergency Use Authorization of medical products: guidance — Emergency Use Authorization of medical products. Silver Spring, MD: Food and Drug Administration, 2009. (Accessed November 2, 2009, at http://www.fda.gov/RegulatoryInformation/Guidances/ucm125127.htm.)
2
Emergency Use Authorization of peramivir: fact sheet for health care providers. Silver Spring, MD: Food and Drug Administration, 2009. (Accessed November 2, 2009, at http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187811.pdf.)
3
Emergency Use Authorization of peramivir: fact sheet for patients and parents/caregivers. Silver Spring, MD: Food and Drug Administration, 2009. (Accessed November 2, 2009, at http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187799.pdf.)
- Citing Articles (38)
Citing Articles
1
Ulrike Grienke, Michaela Schmidtke, Susanne von Grafenstein, Johannes Kirchmair, Klaus R. Liedl, Judith M. Rollinger. (2012) Influenza neuraminidase: A druggable target for natural products. Natural Product Reports 29:1, 11
CrossRef2
S. Doshi, L. Kamimoto, L. Finelli, A. Perez, A. Reingold, K. Gershman, K. Yousey-Hindes, K. Arnold, P. Ryan, R. Lynfield, C. Morin, J. Baumbach, E. B. Hancock, N. M. Bennett, S. Zansky, A. Thomas, W. Schaffner, A. M. Fry. (2011) Description of Antiviral Treatment Among Adults Hospitalized With Influenza Before and During the 2009 Pandemic: United States, 2005-2009. Journal of Infectious Diseases 204:12, 1848-1856
CrossRef3
Michael G Ison. (2011) Antivirals and resistance: influenza virus. Current Opinion in Virology 1:6, 563-573
CrossRef4
Robin Thomson, Mark von Itzstein. 2011. Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza. , 383-400.
CrossRef5
Paolo Preziosi. (2011) Influenza pharmacotherapy: present situation, strategies and hopes. Expert Opinion on Pharmacotherapy 12:10, 1523-1549
CrossRef6
Mas Suhaila, Julian W. Tang, Hong Kai Lee, Cui Lin, Paul A. Tambyah, Hui Kim Yap, Seng Hock Quak, Evelyn S. C. Koay. (2011) Mixtures of Oseltamivir-sensitive and -resistant Pandemic Influenza A/H1N1/2009 Viruses in Immunocompromised Hospitalized Children. The Pediatric Infectious Disease Journal 30:7, 625-627
CrossRef7
Gabriele Neumann, Yoshihiro Kawaoka. (2011) The first influenza pandemic of the new millennium. Influenza and Other Respiratory Viruses 5:3, 157-166
CrossRef8
Eva Montané, Josep Lecumberri, María Luisa Pedro-Botet. (2011) Gripe A, embarazo y antivíricos inhibidores de la neuraminidasa. Medicina Clínica 136:15, 688-693
CrossRef9
Olli Ruuskanen, Elina Lahti, Lance C Jennings, David R Murdoch. (2011) Viral pneumonia. The Lancet 377:9773, 1264-1275
CrossRef10
S. Jain, A. M. Fry. (2011) Peramivir: Another Tool for Influenza Treatment?. Clinical Infectious Diseases 52:6, 707-709
CrossRef11
J. E. Hernandez, R. Adiga, R. Armstrong, J. Bazan, H. Bonilla, J. Bradley, R. Dretler, M. G. Ison, J. E. Mangino, S. Maroushek, A. K. Shetty, A. Wald, C. Ziebold, J. Elder, A. S. Hollister, W. Sheridan, . (2011) Clinical Experience in Adults and Children Treated with Intravenous Peramivir for 2009 Influenza A (H1N1) Under an Emergency IND Program in the United States. Clinical Infectious Diseases 52:6, 695-706
CrossRef12
Brooke Courtney. (2011) Five Legal Preparedness Challenges for Responding to Future Public Health Emergencies. The Journal of Law, Medicine & Ethics 39, 60-64
CrossRef13
Avinash K. Shetty, Gregory A. Ross, Thomas Pranikoff, Larissa V. Gubareva, Catherine Sechrist, Derek M. Guirand, Jon Abramson, Jen-Jar Lin. (2011) Oseltamivir-resistant 2009 H1N1 influenza pneumonia during therapy in a renal transplant recipient. Pediatric Transplantationno-no
CrossRef14
I. F. Hung, K. K. To, C.-K. Lee, K.-L. Lee, K. Chan, W.-W. Yan, R. Liu, C.-L. Watt, W.-M. Chan, K.-Y. Lai, C.-K. Koo, T. Buckley, F.-L. Chow, K.-K. Wong, H.-S. Chan, C.-K. Ching, B. S. Tang, C. C. Lau, I. W. Li, S.-H. Liu, K.-H. Chan, C.-K. Lin, K.-Y. Yuen. (2011) Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection. Clinical Infectious Diseases 52:4, 447-456
CrossRef15
María Alonso, Belén Rodríguez-Sánchez, Maddalena Giannella, Pilar Catalán, Jorge Gayoso, Juan Carlos López Bernaldo de Quirós, Emilio Bouza, Darío García de Viedma. (2011) Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza. Journal of Clinical Virology 50:2, 114-118
CrossRef16
A S Hollister, W P Sheridan. (2011) The Emergency Use Authorization of Peramivir IV: A View from the Manufacturer. Clinical Pharmacology & Therapeutics 89:2, 172-174
CrossRef17
Andrew R. Martin, Curtis D. Collins, Michael Otto, Anurag Malani, Sandro Cinti. (2011) Peramivir. Infectious Diseases in Clinical Practice 19:1, 11-15
CrossRef18
Silvia Meschi, Marina Selleri, Eleonora Lalle, Licia Bordi, Maria B Valli, Federica Ferraro, Giuseppe Ippolito, Nicola Petrosillo, Francesco N Lauria, Maria R Capobianchi. (2011) Duration of viral shedding in hospitalized patients infected with pandemic H1N1. BMC Infectious Diseases 11:1, 140
CrossRef19
Joanne Bronson, Murali Dhar, William Ewing, Nils Lonberg. 2011. To Market, To Market—2010. , 433-502.
CrossRef20
Nicole H. Tobin, Angela J.P. Campbell, Danielle M. Zerr, Ann J. Melvin. 2011. Life-Threatening Viral Diseases and Their Treatment. , 1324-1335.
CrossRef21
C. Renaud, S.A. Pergam, C. Polyak, R. Jain, J. Kuypers, J.A. Englund, L. Corey, M.J. Boeckh. (2010) Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transplant Infectious Disease 12:6, 513-517
CrossRef22
V Arya, W W Carter, S M Robertson. (2010) The Role of Clinical Pharmacology in Supporting the Emergency Use Authorization of an Unapproved Anti-Influenza Drug, Peramivir. Clinical Pharmacology & Therapeutics 88:5, 587-589
CrossRef23
Sujata Subramanian, Jonna D. Clark, Howard E. Jeffries, D. Michael McMullan. (2010) Novel pH1N1 viral cardiomyopathy requiring veno-venous extracorporeal membrane oxygenation*. Pediatric Critical Care Medicine 11:6, 714-717
CrossRef24
Nicolas Widmer, Pascal Meylan, Anton Ivanyuk, Manel Aouri, Laurent A. Decosterd, Thierry Buclin. (2010) Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza. Clinical Pharmacokinetics 49:11, 741-765
CrossRef25
Michael G Ison. (2010) Influenza, including the novel H1N1, in organ transplant patients. Current Opinion in Infectious Diseases 23:4, 365-373
CrossRef26
Helena C. Maltezou. (2010) Novel (pandemic) influenza A H1N1 in healthcare facilities: Implications for prevention and control. Scandinavian Journal of Infectious Diseases 42:6-7, 412-420
CrossRef27
R. B. Moss, R. T. Davey, R. T. Steigbigel, F. Fang. (2010) Targeting pandemic influenza: a primer on influenza antivirals and drug resistance. Journal of Antimicrobial Chemotherapy 65:6, 1086-1093
CrossRef28
Julian W Tang, Nandini Shetty, Tommy Tsan-Yuk Lam. (2010) Features of the new pandemic influenza A/H1N1/2009 virus: virology, epidemiology, clinical and public health aspects. Current Opinion in Pulmonary Medicine 16:3, 235-241
CrossRef29
Robert S. Jones, Samantha Cunningham. (2010) 2009 H1N1 influenza: a pandemic. Osteopathic Family Physician 2:3, 60-65
CrossRef30
Guillermo Domínguez-Cherit, Silvio A. Ñamendys-Silva, Alethse Torre, Alejandro E. Macias, Jose Angel Cordova-Villalobos. (2010) H1N1 Influenza Pandemic of 2009 Compared With Other Influenza Pandemics: Epidemiology, Diagnosis, Management, Pulmonary Complications, and Outcomes. Current Infectious Disease Reports 12:3, 204-210
CrossRef31
Charles L. Sprung, Jozef Kesecioglu. (2010) Chapter 5. Essential equipment, pharmaceuticals and supplies. Intensive Care Medicine 36:S1, 38-44
CrossRef32
M.A. Bürkle, L. Frey, B. Zwißler. (2010) Neue Influenza-A/H1N1-2009-Virus-Pandemie. Der Anaesthesist 59:1, 11-22
CrossRef33
Edith Bennack, Ulrike Holzgrabe. (2010) Notfallzulassung von Peramivir in den USA. Pharmazie in unserer Zeit 39:1, 9-10
CrossRef34
Ankica Jelenkovic. (2010) Counterfeit drugs and other products and substances: Review of drugs for influenza prevention and treatment including pandemic influenza A(H1N1) 2009. Vojnosanitetski pregled 67:6, 501-506
CrossRef35
A. Pop-Vicas, S. Gravenstein. (2010) Influenza in the Elderly – A Mini-Review. Gerontology
CrossRef36
Marcos I. Restrepo, Marcela Mazo, Antonio Anzueto. (2010) Gripe A (H1N1). Experiencia de Estados Unidos. Archivos de Bronconeumología 46, 13-18
CrossRef37
Arturo Huerta García, Nuria González Sánchez, Antoni Torres Martí. (2010) Influenza A (H1N1): manifestaciones clínicas e indicaciones profilácticas y terapéuticas. Archivos de Bronconeumología 46, 19-23
CrossRef38
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Uyeki, Timothy M., Sharma, Amita, Branda, John A., . (2009) Case 40-2009. New England Journal of Medicine 361:26, 2558-2569
Full Text
